ERBB2 and breast carcinoma: In this first-in-human study (ClinicalTrials.gov Identifier: NCT05203497), 99mTc-ZHER2:41071 was evaluated in patients with primary HER2-positive and HER2-low or HER2-negative breast cancer as discriminated based on standard IHC/ISH biopsy results.